Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 390.40K | 307.40K | 187.50K | 29.60K | 18.00K |
Total Receivables | -- | -- | -- | 800.00 | 100.00 |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 175.60K | 487.00K | 145.80K | 210.20K | 246.00K |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 83.40K | 182.30K | 426.70K | 559.70K | 744.70K |
Total Current Assets | 649.50K | 976.80K | 760.00K | 800.20K | 1.01M |
|
|||||
Total Current Assets | 649.50K | 976.80K | 760.00K | 800.20K | 1.01M |
Net Property, Plant & Equipment | 16.80K | 29.50K | 42.00K | 56.20K | 70.20K |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | -- | -- | -- | -- | -- |
Total Assets | 666.30K | 1.01M | 802.00K | 856.40K | 1.08M |
|
|||||
Total Accounts Payable | 744.00K | 1.11M | 1.38M | 1.32M | 1.37M |
Total Accrued Expenses | 2.36M | 2.35M | 1.69M | 3.54M | 3.25M |
Short-term Debt | 124.60K | 206.50K | 110.50K | 109.90K | 190.90K |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 2.45M | 2.98M | 2.69M | 2.94M | 2.99M |
Total Finance Division Other Current Liabilities | 57.50K | 336.10K | 350.40K | 460.20K | 715.20K |
Total Other Current Liabilities | 57.50K | 336.10K | 350.40K | 460.20K | 715.20K |
Total Current Liabilities | 5.74M | 6.98M | 6.22M | 8.37M | 8.52M |
|
|||||
Total Current Liabilities | 5.74M | 6.98M | 6.22M | 8.37M | 8.52M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | 124.60K | 206.50K | 110.50K | 109.90K | 190.90K |
Capital Leases | -- | -- | -- | -- | 12.70K |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 5.74M | 6.98M | 6.22M | 8.37M | 8.53M |
|
|||||
Common Stock & APIC | 253.51M | 251.51M | 249.68M | 246.58M | 245.78M |
Retained Earnings | -258.56M | -257.42M | -255.06M | -254.04M | -253.19M |
Treasury Stock & Other | -60.70K | -60.70K | -60.20K | -60.50K | -60.60K |
Total Common Equity | -5.12M | -5.97M | -5.44M | -7.53M | -7.47M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | 14.40K | 14.10K | 14.00K | 13.00K | 23.00K |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | 14.40K | 14.10K | 14.00K | 13.00K | 23.00K |
|
|||||
Total Common Equity | -5.12M | -5.97M | -5.44M | -7.53M | -7.47M |
Total Preferred Equity | 14.40K | 14.10K | 14.00K | 13.00K | 23.00K |
Total Minority Interest | 33.80K | -9.90K | -- | -- | -- |
Total Equity | -5.07M | -5.97M | -5.42M | -7.51M | -7.45M |
|